The Current Ratio as of December 2024 (TTM) for Replimune Group, Inc. (REPL) is 10.11

According to Replimune Group, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 10.11. This represents a change of -13.41% compared to the average of 11.67 of the last 4 quarters.

Replimune Group, Inc. (REPL) Historical Current Ratio (quarterly & annually)

How has REPL Current Ratio performed in the past?

The mean historical Current Ratio of Replimune Group, Inc. over the last ten years is 16.71. The current 10.11 Current Ratio has changed 5.95% with respect to the historical average. Over the past ten years (40 quarters), REPL's Current Ratio was at its highest in in the September 2018 quarter at 40.56. The Current Ratio was at its lowest in in the June 2017 quarter at 0.

Replimune Group, Inc. (REPL) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Replimune Group, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Replimune Group, Inc. (REPL) Average Current Ratio

How has REPL Current Ratio performed in the past?

The current Current Ratio of Replimune Group, Inc. (REPL) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Replimune Group, Inc. (REPL) Current Ratio vs. Peers

How is REPL’s Current Ratio compared to its peers?

Replimune Group, Inc.’s Current Ratio is less than Nuvalent, Inc. (23.07), less than Ventyx Biosciences, Inc. (23.52), greater than Ascendis Pharma A/S (1.16), greater than United Therapeutics Corporation (4.58), greater than Nuvectis Pharma, Inc. (2.74), greater than Lyra Therapeutics, Inc. (3.64), greater than Kronos Bio, Inc. (8.32), greater than Gossamer Bio, Inc. (6.74), less than Kura Oncology, Inc. (11.47), less than Protagonist Therapeutics, Inc. (10.70), greater than Merus N.V. (8.32), less than Cerevel Therapeutics Holdings, Inc. (10.22), greater than Aerovate Therapeutics, Inc. (8.78), less than Keros Therapeutics, Inc. (19.03), greater than Syndax Pharmaceuticals, Inc. (6.99), greater than Mineralys Therapeutics, Inc. (8.55), less than Crinetics Pharmaceuticals, Inc. (16.38), less than NewAmsterdam Pharma Company N.V. (10.61), greater than PureTech Health plc (3.68),

Build a custom stock screener for Replimune Group, Inc. (REPL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Replimune Group, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Replimune Group, Inc. (REPL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Replimune Group, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.